Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells

@article{Coldwell1999ComparisonOT,
  title={Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells},
  author={Martyn C. Coldwell and Izzy Boyfield and Terry Brown and Jim J. Hagan and Derek N. Middlemiss},
  journal={British Journal of Pharmacology},
  year={1999},
  volume={127}
}
The aim of the present study was to characterize functional responses to ropinirole, its major metabolites in man (SKF‐104557 (4‐[2‐(propylamino)ethyl]‐2‐(3H) indolone), SKF‐97930 (4‐carboxy‐2‐(3H) indolone)) and other dopamine receptor agonists at human dopamine D2(long) (hD2), D3 (hD3) and D4.4 (hD4) receptors separately expressed in Chinese hamster ovary cells using microphysiometry. All the receptor agonists tested (ropinirole, SKF‐104557, SKF‐97930, bromocriptine, lisuride, pergolide… 
Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole
TLDR
In conclusion, antiparkinson agents behave as potent agonists at D3/D2‘heterodimers’, though any role in their actions in vivo remains to be demonstrated.
S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: II. Actions in Rodent, Primate, and Cellular Models of Antiparkinsonian Activity in Comparison to Ropinirole
TLDR
S32504 displays potent and stereospecific activity in rodent, primate, and cellular models of antiparkinsonian properties and engagement of D3 receptors contributes to its neuroprotective properties.
S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: I. Cellular, Electrophysiological, and Neurochemical Profile in Comparison with Ropinirole
TLDR
D3/D2 agonist and antiparkinsonian agent ropinirole mimicked the profile of S32504, which is a potent and selective agonist at dopamine D3 and D2 receptors.
Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. II. Agonist and Antagonist Properties at Subtypes of Dopamine D2-Like Receptor and α1/α2-Adrenoceptor
TLDR
In conclusion, antiparkinson agents display diverse agonist and antagonist properties at multiple subtypes of D2-like receptor and α1/α2-AR, actions, which likely contribute to their contrasting functional profiles.
Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum
TLDR
The hypothesis that the antiparkinsonian effect of dopamine receptor agonists is mediated by a more complex interactions with dopamine receptor subtypes than currently believed is supported.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 59 REFERENCES
Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin.
TLDR
Native D3 receptors in brain are characterized by an unusually high nanomolar affinity for dopamine and a low modulatory influence of guanyl nucleotides on agonist binding, which suggest that D3 receptor are involved in a peculiar mode of neurotransmission in a restricted subpopulation of dopamine neurons.
Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.
Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist
Lack of Discrimination by Agonists for D2 and D3 Dopamine Receptors
A functional test identifies dopamine agonists selective for D3 versus D2 receptors.
TLDR
The known behavioural actions of D3 selective agonists support a role for the D3 receptor in motor inhibitions, which should be taken into account for the treatment of motor dysfunctions by dopamine agonists.
Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907
TLDR
The new compound [3H]PD 128907 appears to be a suitable radioligand for autoradiographic examination of the D3-dopamine receptor localisation in the human brain, and should also be useful for pharmacological studies of this receptor subtype.
[3H]7-OH-DPAT is capable of labeling dopamine D2 as well as D3 receptors.
Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain.
TLDR
Binding of [125I]epidepride to D3-like receptors was negligible in the dorsal striatum but was concentrated in islands of dense binding in the nucleus accumbens and ventral putamen that aligned with acetylcholinesterase-poor striosomes.
...
1
2
3
4
5
...